OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,000.00
-80.00 (-0.99%)
At close: Feb 13, 2026
Market Cap141.17B +35.5%
Revenue (ttm)87.58B +11.1%
Net Income11.18B +17.6%
EPS731.00 +17.4%
Shares Out17.65M
PE Ratio10.94
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume114,853
Average Volume179,353
Open8,080.00
Previous Close8,080.00
Day's Range7,890.00 - 8,200.00
52-Week Range5,610.00 - 8,960.00
Beta0.47
RSI58.30
Earnings DateJan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 159
Stock Exchange KOSDAQ
Ticker Symbol 131030
Full Company Profile

Financial Performance

In 2024, OPTUS Pharmaceutical's revenue was 81.90 billion, an increase of 13.09% compared to the previous year's 72.43 billion. Earnings were 10.31 billion, a decrease of -4.20%.

Financial Statements